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INTRODUCTION 
Acute pancreatitis is defined as an acute inflammatory process of the pancreas 
that frequently involves peripancreatic tissues and / or remote organ systems. 
With Increasing incidences of Acute Pancreatitis and its fulminant nature of 
progression, it has become mandatory to adopt Guidelines, adherence of which 
produces Optimum results. 
The study will be based on seeing the efficacy and recovery of patients 
diagnosed with acute pancreatitis by adopting the guidelines given by American 
College of Gastroenterologists. 
Guidelines adopted in our unit, Department of General Surgery for the 
management of acute pancreatitis (AP) are based on the Western experience. 
The guidelines have been applied in our setup with available resources. Before 
applying the guidelines in our patients, thorough study was done and many 
literatures reviewed.  
Many studies are showing that American Guidelines are difficult to extrapolate 
in our Indian Setting, but I have shown in this study that the Guidelines given 
by American College of Gastroenterologists can be applied in our set up also 
and adherence of Guidelines based management decreases the morbidity and 
mortality of patients with acute pancreatitis. The statistics and the results of the 
guidelines based approach is given in the later pages of this dissertation.  
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GROSS ANATOMIC CONSIDERATIONS OF PANCREAS 
The adult human pancreas weighs about 80 g. FIGURE 1 shows the anatomical 
relationship between the pancreas and rest of the organs surrounding it in the 
abdomen. The pancreas is a retroperitoneal organ and it does not have a capsule. 
The second and third portions of the duodenum curve around the head of the 
pancreas. The spleen is adjacent to the pancreatic tail. The regions of the 
pancreas are the head, body, tail and uncinate process and vasculature is given 
in FIGURE 2. The distal end of the common bile duct passes through the head 
of the pancreas and joins the pancreatic duct entering the duodenum ( FIGURE 
1). For this reason, pathologic processes of the pancreas, such as a cancer at the 
head of the pancreas or swelling and/or scarring of the head of the pancreas due 
to pancreatitis, can lead to biliary system obstruction and injury. 
Diseases, such as pancreatitis and pancreatic cancer, can involve the splenic 
vein leading to its thrombosis and vascular engorgement of the spleen due to the 
obstruction of venous blood flow. 
The pancreas is innervated by both the parasympathetic and sympathetic 
nervous systems. The efferent parasympathetic system is contained within the 
branches of the vagus nerve that originates in the dorsal vagal complex (tenth 
cranial nerve nucleus) of the brain. The terminal branches of the vagus synapse 
with intrapancreatic ganglia. The postganglionic fibers innervate both exocrine 
and endocrine structures. The sympathetic innervation orginates in the lateral  
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.  
FIGURE 1 
Cross-sectional anatomy of the pancreas. This diagram represents the anatomical features of a 
“slice” of the abdomen at the level depicted in the upper right hand corner of the figure. 
Anterior to the pancreas are the stomach, colon, omentum and loops of small intestine. 
Posterior to the pancreas are the portal vein, inferior vena cava, aorta, superior mesenteric 
artery and vein, kidneys and vertebrae. The distal common bile duct passes through the head 
of the pancreas. Adapted from Gorelick F, Pandol, SJ, Topazian M. Pancreatic physiology, 
pathophysiology, acute and chronic pancreatitis. Gastrointestinal Teaching Project, 
American Gastroenterologic Association. 2003. 
 
FIGURE 2 
Pancreatic vascular system. The arterial blood supply to the pancreas is from two major 
arteries supplying the abdominal organs, the celiac and superior mesenteric arteries. The 
celiac artery branch supplying the pancreas is the superior pancreaticoduodenal artery. The 
superior mesenteric artery branch supplying the pancreas is the inferior pancreaticoduodenal 
artery. Venous drainage of the pancreas is via the splenic vein and the superior mesenteric 
vein emptying into the portal vein. Adapted from Gorelick F, Pandol, SJ, Topazian M. 
Pancreatic physiology, pathophysiology, acute and chronic pancreatitis. Gastrointestinal 
Teaching Project, American Gastroenterologic Association. 2003. 
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 grey matter of the thoracic and lumbar spinal cord. The bodies of the 
postganglionic sympathetic neurons are located in the hepatic and celiac 
plexuses. The postganglionic fibers innervate blood vessels of the pancreas. 
FUNCTIONAL ANATOMIC CONSIDERATIONS 
 It is important to point out that there are important interrelationships between 
the endocrine (islets of  Langerhans) and exocrine pancreas( Acinar cell and 
duct tissue ). The illustration in FIGURE 3 points out this relationship. The 
exocrine portion, comprising 85% of the mass of the pancreas, secretes 
digestive enzymes, water and NaHCO3 into the duodenum. The endocrine 
portion secretes its hormones into the blood stream. The blood flow from the 
endocrine pancreas passes to the exocrine pancreas before entering the general 
circulation. 
                         
 
FIGURE 3 
The exocrine and endocrine pancreas.  
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Anatomic studies demonstrate that the blood flow from the endocrine pancreas 
enters the capillaries of the exocrine tissue surrounding each of the islets before 
entering the general circulation. This “portal” system provides for the delivery 
of very high concentrations of hormones from the islets of Langerhans to the 
exocrine tissue surrounding the Islets. The hormones from the islets of 
Langerhans include insulin, amylin, glucagon, somatostatin and pancreatic 
polypeptide. Although the full significance of the effects of these hormones on 
the exocrine pancreas is not known, the acinar cells of the pancreas have insulin 
receptors that are involved in regulation of digestive enzyme synthesis of the 
exocrine pancreas. 
The functional unit of the exocrine pancreas is composed of an acinus and its 
draining ductule (FIGURE 3). The ductal system extends from the lumen of the 
acinus to the duodenum. A ductule from the acinus drains into interlobular 
(intercalated) ducts, which in turn drain into the main pancreatic ductal system. 
The acinus (from the Latin term meaning “berry in a cluster”) can be spherical 
or tubular (FIGURE 3) or can have some other irregular form. The acinar cells 
of the acinus are specialized to synthesize, store, and secrete digestive enzymes. 
On the basolateral membrane are receptors for hormones and neurotransmitters 
that stimulate secretion of the enzymes. The basal aspect of the cell contains the 
nucleus as well as abundant rough endoplasmic reticulum for protein synthesis. 
The apical region of the cell contains zymogen granules and store digestive 
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enzymes. The apical surface of the acinar cell also possesses microvilli. Within 
the microvilli and in the cytoplasm underlying the apical plasma membrane is a 
filamentous actin meshwork that is involved in exocytosis of the contents of the 
zymogen granules. Secretion is into the lumen of the acinus, which is connected 
to the ductal system. Tight junctions between acinar cells form a band around 
the apical aspects of the cells and act as a barrier to prevent passage of large 
molecules, such as the digestive enzymes. The junctional complexes also 
provide for the paracellular passage of water and ions. 
Another intercellular connection between acinar cells is the gap junction. This 
specialized area of the plasma membrane between adjacent cells acts as a pore 
to allow small molecules (molecular weight 500 to 1000 Da) to pass between 
cells. The gap junction allows chemical and electrical communication between 
cells. 
The duct cell epithelium consists of cells that are cuboidal to pyramidal and 
contain the abundant mitochondria necessary for energy products needed for ion 
transport (FIGURE 4). Another cell that is situated at the junction of the acinus 
and ductule is the centroacinar cell. This cell has ductal cell characteristics but 
is also likely a progenitor for different cell types for the pancreas. The duct cells 
as well as the centroacinar cells contain carbonic anhydrase, which is important 
for their ability to secrete bicarbonate . 
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Another cell that is becoming important because of its role in pathologic states 
is the pancreatic stellate cell (PaSC). This is a very slender star-shaped (hence 
the name stellate) cell that drapes itself around the acinar and ductular structures 
as well as the islets of Langerhans. The role of PaSCs in normal function is 
probably to lay down the basement membrane to direct proper formation of the 
epithelial structures. Their role in pathologic states, such as chronic pancreatitis 
and pancreatic cancer, has been of considerable interest. In these diseases, the 
PaSC is trans-formed into a proliferating myofibroblastic cell type that 
synthesizes and secretes extracellular matrix proteins, proinflammatory 
cytokines and growth factors. These actions of the transformed PaSCs are 
central to the inflammatory and fibrosing pathologic processes of chronic 
pancreatitis and are procarcinogenic for pancreatic cancer. In fact, the 
myofibroblastic transformed state of the PaSC is emerging as a key participant 
in both the rate of growth of the cancer and the development of resistance to 
Chemotherapy. 
                   
FIGURE 4 : Ultrastructure of acinar and duct cells of the exocrine pancreas. 
 
 
16 
 
DIGESTIVE ENZYMES AND THEIR FUNCTIONS 
The human pancreas has the largest capacity for protein synthesis of any organ 
in the human body. Much of the capacity is devoted to synthesis of the digestive 
enzymes that are secreted in the intestinal lumen. Some of the enzymes are 
present in more than one form (e.g., cationic trypsinogen, anionic trypsinogen 
and mesotrypsinogen). Further, they are capable of digesting the cell and 
causing significant damage. There are mechanisms to prevent these enzymes 
from potentially digesting the pancreas including storage and packing in acidic 
zymogen granules to inhibit activity; and synthesis and storage as inactive 
precursor forms. Activation of these enzymes takes place in the surface of the 
duodenal lumen, where a brush-border glycoprotein peptidase, enterokinase, 
activates trypsinogen by removing (by hydrolysis) an N-terminal hexapeptide 
fragment of the molecule (Val–Asp–Asp–Asp–Asp–Lys) . The active form, 
trypsin, then catalyzes the activation of the other inactive proenzymes. 
Presumably, these enzymes would not cause pancreatic cellular damage if 
released into the pancreatic cell/tissue because there is no starch, glycogen or 
triglyceride substrate for these enzymes in pancreatic tissue. 
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FIGURE 5 : Intestinal digestive enzyme activation.  
 
Another mechanism that the exocrine pancreas utilizes to prevent intracellular 
activation involves the synthesis and incorporation of a trypsin inhibitor 
(pancreatic secretory trypsin inhibitor [PSTI]) into the secretory pathway and 
zymogen granule. PSTI is a 56-amino acid peptide that inactivates trypsin by 
forming a relatively stable complex with the enzyme near its catalytic site. The 
function of the inhibitor is to inactivate trypsins that are formed 
autocatalytically in the pancreas or pancreatic juice, thus, preventing pancreatic 
digestion and resulting disorders, such as pancreatitis. In the following 
paragraphs are descriptions of the functions of the major digestive enzymes. 
Amylase is secreted by both the pancreas and salivary glands, differing in 
molecular weight, carbohydrate content and electrophoretic mobility. However, 
they have identical enzyme activities. Salivary amylase initiates digestion in the 
mouth and may account for a significant portion of starch and glycogen 
digestion because it is transported with the meal into the stomach and small 
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intestine, where it continues to have activity. Optimal enzyme activity occurs at 
neutral pH. During a meal, gastric pH can approach neutrality despite gastric 
acid secretion because of the buffering from molecules in the meal as well as 
alkaline secretions from the salivary glands and gastric mucus. Salivary amylase 
can contribute up to 50% of starch and glycogen digestion while pancreatic 
amylase contributes the remainder. The brush-border enzymes complete the 
hydrolysis of the products of amylase digestion to glucose. The final product, 
glucose, is transported across the intestinal absorptive epithelial cell by a Na+-
coupled transport. 
Lipases are secreted mainly by the pancreas in contrast to amylase where there 
is a significant salivary contribution. There are lingual and gastric lipases but 
these contribute to fat digestion in only a minor fashion. Major lipases secreted 
by the pancreas are lipase (or triglyceride lipase) and prophospholipases. 
Pancreatic lipase hydrolyzes a triglyceride molecule to two fatty acid molecules 
released from carbons 1 and 3 and a monoglyceride with a fatty acid esterified 
to glycerol at carbon 2 . Lipase binds to the oil/water interface of the 
triglyceride oil droplet, where it acts to hydrolyze the triglyceride. Both bile 
acids and colipase are important for the full activity of lipase. Bile acids aid in 
the emulsification of triglyceride to enlarge the surface area for lipase to act on, 
and they form micelles with fatty acids and monoglyceride, which, in turn, 
remove these products from the oil/water interface. Colipase is believed to form 
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a complex with lipase and bile salts. This ternary complex anchors lipase and 
allows it to act in a more hydrophilic environment on the hydrophobic surface 
of the oil droplet. 
Proteases secreted by the pancreas are generally divided into two groups—the 
endopeptidases and the exopeptidases. All are stored and secreted from the 
pancreas as inactive proforms that are activated in the duodenum by trypsin. 
Trypsin, chymotrypsin and elastase are endopeptidases that cleave specific 
peptide bonds adjacent to specific amino acids within a protein. Exopeptidases 
include carboxypeptidases that cleave peptide bonds at the carboxyl terminus of 
proteins. 
PATHOPHYSIOLOGY OF ACUTE PANCREATITIS 
The pathophysiology of acute pancreatitis is characterized by a loss of 
intracellular and extracellular compartmentation, by an obstruction of pancreatic 
secretory transport and by an activation of pancreatic enzymes. In biliary acute 
pancreatitis, outflow obstruction with pancreatic duct hypertension and a toxic 
effect of bile salts contribute to disruption of pancreatic ductules, with 
subsequent loss of extracellular compartmentation. Alcohol induces functional 
alterations of plasma membranes, alters the balance between proteolytic 
enzymes and protease inhibitors, thus triggering enzyme activation, 
autodigestion and cell destruction. Once the disease has been initiated, the 
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appearance of interstitial edema and inflammatory infiltration are the basic 
features of acute pancreatitis. The accumulation of polymorphonuclear 
granulocytes in pancreatic and extrapancreatic tissue, and the release of 
leukocyte enzymes play an essential role in the further progression of the 
disease and in the development of systemic complications. Activation of 
different cascade systems by proteolytic activity, and consumption of alpha 2-
macroglobulin further characterize the severe clinical course of illness. 
       
FIGURE 6 : PATHOPHYSIOLOGY OF ACUTE PANCREATITIS 
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AMERICAN COLLEGE OF GASTROENTEROLOGY GUIDELINES 
FOR MANAGING ACUTE PANCREATITIS 
Acute pancreatitis (AP) is one of the most common diseases of the 
gastrointestinal tract, leading to tremendous emotional, physical, and financial 
human burden. 
Two distinct phases of AP have now been identified: 
(i) Early (within 1 week), characterized by the Systemic Inflammatory 
Response Syndrome (SIRS) and / or organ failure; and 
(ii) Late ( > 1 week), characterized by local complications. 
 It is critical to recognize the paramount importance of organ failure 
in determining disease severity.  
Local complications are defined as peripancreatic fluid collections, pancreatic 
and peripancreatic necrosis (sterile or infected), pseudocysts, and walled-off 
necrosis 
(sterile or infected). Isolated extrapancreatic necrosis is also included under the 
term necrotizing pancreatitis. 
The guideline first discusses about the diagnosis, etiology, and severity of AP.  
Then focus is given on the early medical management of AP followed by a 
discussion of the management of complicated disease, most notably 
pancreatic necrosis.  
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The evolving issues of antibiotics, nutrition, and endoscopic, radiologic, 
surgical, and other minimally invasive interventions will be addressed. 
 
 
DIAGNOSIS OF ACUTE PANCREATITIS 
RECOMMENDATIONS 
“ 1. The diagnosis of AP is most often established by the presence of two of the 
three following criteria: (i) abdominal pain consistent with the disease, 
(ii) serum amylase and / or lipase greater than three times the upper limit of 
normal, and / or 
(iii) characteristic findings from abdominal imaging 
 
2. Contrast-enhanced computed tomographic (CECT) and / or magnetic 
resonance imaging (MRI) of the pancreas should be reserved for patients in 
whom the diagnosis is unclear or who fail to improve clinically within the first 
24-48 h after hospital admission 
 
ETIOLOGY OF ACUTE PANCREATITIS 
RECOMMENDATIONS 
“1.Transabdominal ultrasound should be performed in all patients with AP 
2. In the absence of gallstones and / or history of significant history of alcohol 
use, a serum triglyceride should be obtained and considered  if > 1,000 mg / dl. 
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3. In a patient > 40 years old, a pancreatic tumor should be considered as a 
possible cause of AP. 
4. Endoscopic investigation of an elusive etiology in patients with AP should be 
limited, as the risks and benefits of investigation in these patients are unclear. 
5.Patients with idiopathic AP (IAP) should be referred to centers of expertise. 
6. Genetic testing may be considered in young patients ( < 30 years old) if no 
cause is evident and family history of  pancreatic disease is present.” 
 
 INITIAL ASSESSMENT AND RISK STRATIFICATION 
RECOMMENDATIONS 
“1. Hemodynamic status should be assessed immediately upon presentation and 
resuscitative measures begun as needed and then reassessed after 6 hrs, 12 hrs, 
24 hrs. and 48 hrs. 
2. Risk assessment should be performed to stratify patients into higher- and 
lower 
risk categories to assist triage and the patients who fail to recover in 24 hours 
should be managed in ICU set up. 
3. Patients with SIRS and organ failure should be transferred  to an intensive 
care unit or intermediary care setting if they fail to improve in first 24 hours.” 
4. Uniformly, severity scoring systems are cumbersome, typically require 48 h 
to become accurate, and when the score demonstrates severe disease, the 
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patient’s condition is obvious regardless of the score. So,the initial management 
at the time of admission should start irrespective of any scoring modality.” 
  
Clinical findings associated with a severe course for initial risk assessment 
Patient characteristics 
Age > 55 years  
Obesity (BMI > 30 kg / m 2 ) 
Altered mental status  
Comorbid disease  
The systemic infl ammatory response syndrome (SIRS)  
Presence of > 2 of the following criteria: 
– pulse > 90 beats / min 
– respirations > 20 / min or PaCO 2 > 32 mm Hg 
– temperature > 38 ° C or < 36 ° C 
– WBC count > 12,000 or < 4,000 cells / mm 3 or > 10 % immature 
neutrophils (bands) 
Laboratory findings 
BUN > 20 mg/dl  
Rising BUN  
HCT > 44 %  
Rising HCT  
Elevated creatinine  
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Radiology findings 
Pleural effusions 
Pulmonary infiltrates  
Multiple or extensive extrapancreatic collections  
 
INITIAL MANAGEMENT 
RECOMMENDATIONS 
“1. Aggressive hydration, defined as 250 – 500 ml per hour of isotonic 
crystalloid solution should be provided to all patients, unless cardiovascular, 
renal, or other related comorbid factors exist. Early aggressive intravenous 
hydration is most beneficial during the first 12 – 24 h, and may have little 
benefit beyond this time period. 
2. In a patient with severe volume depletion, manifest as hypotension and 
tachycardia, more rapid repletion (bolus) may be needed. 
3. Lactated Ringer  s solution may be the preferred isotonic crystalloid 
replacement fluid. 
4. Fluid requirements should be reassessed at frequent intervals within 6 h of 
admission and for the next 24 – 48 h. The goal of aggressive hydration should 
be to decrease the BUN.” 
 
ROLE OF ERCP IN ACUTE PANCREATITIS 
RECOMMENDATIONS 
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“1. Patients with AP and concurrent acute cholangitis should undergo ERCP 
within 24 h of admission. 
2. ERCP is not needed early in most patients with gallstone pancreatitis who 
lack laboratory or clinical evidence of ongoing biliary obstruction. 
3. In the absence of cholangitis and / or jaundice, MRCP or EUS rather than 
diagnostic ERCP should be used to screen for choledocholithiasis if highly 
suspected . 
4. Pancreatic duct stents and / or postprocedure rectal nonsteroidal anti-
inflammatory drug (NSAID) suppositories, e.g..Indomethacin should be utilized 
to lower the risk of severe post-ERCP pancreatitis in high-risk patients.” 
 
THE ROLE OF ANTIBIOTICS IN AP 
RECOMMENDATIONS 
“1. Antibiotics should be given for an extrapancreatic infection, such as 
cholangitis, catheter-acquired infections, bacteremia, urinary tract infections, 
pneumonia. 
2. Routine use of prophylactic antibiotics in patients with severe AP is not 
recommended. 
3. The use of antibiotics in patients with sterile necrosis to prevent the 
development of infected necrosis is not recommended. 
4. Infected necrosis should be considered in patients with pancreatic or 
extrapancreatic necrosis who deteriorate or fail to improve after 7 – 10 days of 
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hospitalization. In these patients, either (i) initial CT-guided fine-needle 
aspiration 
(FNA) for Gram stain and culture to guide use of appropriate antibiotics or (ii) 
empiric use of antibiotics after obtaining necessary cultures for infectious 
agents, without CT FNA, should be given. 
5. In patients with infected necrosis, antibiotics known to penetrate pancreatic 
necrosis, such as carbapenems, quinolones, and metronidazole, may be useful in 
delaying or sometimes totally avoiding intervention, thus decreasing morbidity 
and 
mortality. 
6. Routine administration of antifungal agents along with prophylactic or 
therapeutic antibiotics is not recommended.” 
 
NUTRITION IN AP 
RECOMMENDATIONS 
“1. In mild AP, oral feedings can be started immediately if there is no nausea 
and vomiting, and the abdominal pain has resolved. 
2. In mild AP, initiation of feeding with a low-fat solid diet appears as safe as a 
clear liquid diet. 
3. In severe AP, enteral nutrition is recommended to prevent infectious 
complications. Parenteral nutrition should be avoided, unless the enteral route is 
not available, not tolerated, or not meeting caloric requirements. 
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4. Nasogastric delivery and nasojejunal delivery of enteral feeding appear 
comparable in efficacy and safety.” 
 
THE ROLE OF SURGERY IN AP 
RECOMMENDATIONS 
“1. In patients with mild AP, found to have gallstones in the gallbladder, open / 
lap cholecystectomy should be performed before discharge to prevent a 
recurrence of AP. 
2. In a patient with necrotizing biliary AP, in order to prevent infection, 
cholecystectomy is to be deferred until active inflammation subsides and fluid 
collections resolve or stabilize. 
3. Asymptomatic pseudocysts and pancreatic and / or extrapancreatic 
necrosis do not warrant intervention regardless of size, location, and / or 
extension. 
4. In stable patients with infected necrosis, surgical, radiologic, and / or 
endoscopic drainage should be delayed preferably for more than 4 weeks to 
allow liquefication of the contents and the development of a fibrous wall around 
the necrosis (walled-off necrosis)   
5. In symptomatic patients with infected necrosis, minimally invasive methods 
of necrosectomy are preferred to open necrosectomy.” 
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Based on the above mentioned guidelines, patients were treated in our unit and 
the results are documented in the upcoming pages. Most of the Indian studies 
says that the application of guidelines as such is not feasible in the Indian setup. 
But, this study which has been done in 50 patients over a period of 10 months 
shows that the guidelines can be applied as such in the Indian population and 
adherence of guidelines is must for optimum results. 
 
Further studies are required to test the universality, validity and reliability of the 
guidelines in our healthcare set up.  
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ABSTRACT 
AIM:  To study the outcomes and efficacy of managing Acute pancreatitis 
based on Guidelines by American College of Gastroenterology. 
STUDY DESIGN:  
Prospective study  
MATERIALS AND METHODS  
50 patients who got admitted in our unit which characteristic abdominal pain of 
Acute Pancreatitis were included in the study over a period of 10 months. 
Confirmation done with Blood Investigations and Imaging studies. Aggressive 
fluid management along with analgesics were given and the symptomatic 
improvements( PR, RR, Temp., SpO2) and lab investigations ( Hb, TC, PCV, 
S.amylase ) monitored at the end of 6 hours, 12 hours, 24 hours and 48 hours. 
The etiology, duration of symptoms, co-morbidities were studied. The number 
of Patients with SIRS and organ failure recorded and their recovery from the 
illness monitored. Unnecessary use of Antibiotics avoided and given only to 
those patients who had Infected Pancreatic Necrosis. CECT Abdomen and 
Pelvis done only in those patients who failed to show signs of recovery at the 
end of 24 hours. The patients with SIRS and organ failure at the end of 24 hours 
monitored and managed in ICU setup. The duration of hospital stay recorded. 
All the patients were managed strictly following the guidelines given by 
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American College of Gastroenterology. Severity of Pancreatitis applied based 
on Revised Atlanta Classification( 2013) at the end of 48 hours. Organ Failure 
calculated using Modified Marshall Scoring using ABG Analysis. 
 STATISTICAL ANALYSIS:  
To describe about the data descriptive statistics frequency analysis, percentage 
analysis were used for categorical variables and repeated measures ANOVA for 
continuous variables. Repeated measures ANOVA showed statistically 
significant variance for Pulse Rate, Respiratory Rate, Temperature and Total 
Count at the time of admission, at 6th hour, 12th hour, 24th hour and 48th hour. 
The probability value 0.05 is considered as significant level.  
RESULTS: 
Out of the 50 patients admitted with Acute Pancreatitis, 32 patients were in 
SIRS and 4 patients were with Organ Failure. The patients were managed based 
on ACG Guidelines. At the end of 48 hours, 27/32 patients got completely 
recovered from SIRS and 3/ 4 patients completely recovered from organ failure. 
Only 11 patients required both USG and CECT Abdomen as they failed to show 
signs of recovery at the end of 24 hours. Antibiotics given only in 8 patients. 
Out of the 50 patients, 4 patients underwent Laparoscopic Cholecystectomy. 25 
patients were diagnosed of mild pancreatitis, 24 as Moderately severe Acute 
Pancreatitis and 1 with severe pancreatitis. The duration of hospital stay varied 
 
 
32 
 
from 6-25 days. No deaths occurred during the period of study. 
CONCLUSION: 
Guidelines based management give optimum results in patients with Acute 
pancreatitis. Initial 24- 48 hours is the crucial period in the management of 
Acute pancreatitis. Failure of Aggressive fluid challenge in the patients will lead 
to irreversible necrotic changes in the Pancreas. Further studies are required to 
test the universality, validity of adopting the ACG Guidelines as such in our 
setup.  
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AIMS & OBJECTIVES:  
-To study the mode of  Presentation, Etiology, Course and Recovery from acute 
pancreatitis based on Guidelines suggested by American College of 
Gastroenterology. 
-To focus on adopting a guidelines based approach towards the illness and 
reduce variation in practice. 
 
MATERIALS AND METHODS 
PLACE OF STUDY: Department of General Surgery, S6 unit, Govt.  Stanley 
Medical College &Hospital, Chennai 
DURATION: 
10 months ( NOV.2016 to SEPT. 2017) 
STUDY DESIGN: 
Prospective study 
 
SAMPLE SIZE : 50 cases 
 
INCLUSION CRITERIA : 
All adult patients with clinical, Laboratory Investigations and Imaging studies 
showing features of Acute Pancreatitis. 
Patients with first episode of Acute  Pancreatitis. 
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EXCLUSION CRITERIA: 
Patients with chronic Pancreatitis 
Patients with acute on chronic pancreatitis 
Patients with malignancy. 
 
METHODOLOGY 
 All newly diagnosed cases of Acute Pancreatitis as per the guidelines 
given by American College of Gastroenterology( ACG ) were subjected 
to aggressive fluid management irrespective of the scoring at the time of 
admission because severity scoring systems typically require 48 hours to 
become accurate. 
 
 Various factors associated with etiology, clinical signs, sensitivity as a 
diagnostic tool, treatment outcomes, complications., etc were assessed 
with the help of a well structured clinical proforma. 
 
 Patients after institution of aggressive fluid management and analgesics  
were reassessed after 6 hours, 12hours, 24 hours and 48 hours to know 
the response to treatment based on symptomatic improvement and blood 
investigations as given in the proforma. 
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 CECT Abdomen and Pelvis will be taken only if there is no improvement 
after 24 hours with aggressive fluid management. 
 
 
 Antibiotics are recommended only after 24 hours when the patient is 
deteriorating and imaging studies showing Acute Necrotizing Pancreatitis 
( Infected Necrosis ).  
 
 Antibiotic of Choice will be MEROPENEM / IMIPENEM depending on 
the availability. In case of inavailability of the drug, the patient will be 
put on CIPROFLOXACIN , 3rd choice of drug will be CEFTRIAXONE. 
 
 The patient will be classified as Mild, Moderately Severe and Severe 
Pancreatitis after 48 hours of Admission based on Revised Atlanta 
Classification (2013) 
 
CRITERIA FOR SIRS – More than two of the following ( to be seen at the 
end of 6, 12, 24, 48 hours ) 
HR > 90 BEATS/MIN 
TEMP < 36 DEGREE OR > 38 DEGREE 
RR > 20/MIN or paCO2 > 32 
WBC COUNT < 4000 cells/cumm or > 12000 cells /cu.mm 
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MODIFIED MARSHALL SCORE( more than 2 in any of the organs 
indicated organ failure) by ABG Analysis. 
 
 
FiO2  
At room air              -                 21                            4 l/min nasal O2          -  30 
2 l/min nasal O2      -                 25                            6-8 l/min nasal O2       -  40 
 
 If the patient is not improving in 24 hours with persistant SIRS, patient 
will be shifted to an ICU setup and monitored. 
 The following data will be recorded -  
          -Recovery from SIRS 
          -Patients requiring ICU Care 
          -Patients with Biliary Pancreatitis 
          -Patients requiring surgery 
ORGAN 
SYSTEM 
SCORE 0 1 2 3 4 
paO2/FiO2 >400 301 - 400 201-300 101-200 <=101 
Renal 
S.Creatinine 
<1.4 1.4- 1.8 1.9 -3.5 3.6 -4.9 >4.9 
Systolic BP >90 <90, fluid 
responsive 
<90, fluid 
unresponsive 
<90, 
ph<7.3 
<90, 
ph<7.2 
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 Initiation of orals in case of recovery or time of Interventional Procedure 
in case of severe course of the disease will be instituted as per the ACG 
Guidelines. 
 
SEVERITY OF PANCREATITIS 
Based on Atlanta Revision Criteria (2013), Patient will be classified as follows - 
MILD ACUTE PANCREATITIS 
Absence of organ failure 
Absence of Local Complications 
( Peripancreatic fluid collections/ Pancreatic and Peripancreatic Necrosis (sterile 
or infected)/ Pseudocysts, and walled-off Necrosis (Sterile or Infected). 
 
MODERATELY SEVERE ACUTE PANCREATITIS 
Local complications AND/OR 
Transient Organ failure ( < 48 hours ) 
 
SEVERE ACUTE PANCREATITIS 
Persistent organ failure > 48 hours 
( Organ failure described by Modified Marshall Scoring ) 
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DATA HANDLING AND STATISTICAL ANALYSIS 
 
Data was collected by the principal investigator using pre-designed data 
collection sheets. Frequency tables and summary statistics were made for the 
socio-demographic characteristics and the various outcome variables in the 
study. Means, medians were calculated. To describe about the data descriptive 
statistics frequency analysis, percentage analysis were used for categorical 
variables and repeated measures ANOVA for continuous variables. Repeated 
measures ANOVA showed statistically significant variance for Pulse Rate, 
Respiratory Rate, Temperature and Total Count at the time of admission, at 6th 
hour, 12th hour, 24th hour and 48th hour. The probability value 0.05 is considered 
as significant level.  
 
 
ETHICAL CONSIDERATIONS 
The study commenced upon approval by the Department of Surgery and 
Institutional Ethical Committee ( IEC).  Informed consent was obtained from 
each participant prior to enrolment in the study. A pre-consent counselling of 
the participants was done .The next of kin signed consent on behalf of 
participants who were unable to do so. Those who declined participation were 
not denied treatment they deserved because of their decision not to participate. 
There was no extra cost incurred for participating in the study. 
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RESULTS 
A prospective study for ten months of all adult patients with clinical, laboratory 
Investigations and Imaging studies showing features of acute pancreatitis (first 
episode of acute pancreatitis as per the guidelines given by American College of 
Gastroenterologists) were subjected to aggressive fluid management irrespective 
of the scoring at the time of admission. Various factors associated with 
aetiology, clinical signs, sensitivity, treatment outcomes, complications, 
etc.were assessed and the Patients after institution of aggressive fluid 
management and analgesics were reassessed after 6 hours, 12hours, 24 hours 
and 48 hours to know the response to treatment based on symptomatic 
improvement and blood investigations. The analysis yields the following 
findings.  
 
Age distribution of the sample 
The following figure illustrates the age distribution of the participants with 
mean age of 33.14 (S.D=6.263).  
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Chart 1 : Age distribution of the sample 
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Sex distribution of the sample 
 
Majority of the patients were males (92%, n=46). The following figure 
illustrates this. 
 
 
 
Chart 2: Gender distribution of the sample 
 
 
 
Female
8%
Male
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Clinical Presentation of the illness 
Majority of the patients reported epigastric guarding and tenderness (68%, 
n=34). The following picture depicts clinical presentation. 
 
 
 
 
Chart 3: Clinical presentation of the sample 
 
 
 
Duration of illness 
The following image shows the duration of illness. Majority of them had two 
days of illness before seeking medical attention (38%, n=19). 
68
20
8
4
Epigastric guarding and
tenderness
Only epigastric tenderness Abdominal Distension No tenderness, Only
upper quadrant pain
Clinical Presentation
Clinical Presentation
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Chart 4: Duration of illness 
 
 
 
 
Comorbid conditions  
The following picture shows the comorbid conditions of the patients. Diabetic is 
the most common comorbid condition (12%, n=6).  
32
38
30
1
2
3
Duration of illness
Duration of illness
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Chart 5: Comorbidities 
 
 
 
 
Smoking and alcoholism 
Out of 50 patients, 36 patients were smokers while 39 of them were alcoholics. 
 
74%
6%
12%
8%
Comorbidities
No Asthma Diabetic Hypertension
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Chart 6: Smoking and alcoholism of the sample 
 
 
Patients with SIRS (Systemic Inflammatory Response Syndrome) 
The number of patients with SIRS was 32 in number. The following section 
illustrates the findings in the patients with SIRS.  The following figure 
illustrates the age distribution with a mean of 33.72 (S.D=6.264, n=32).  
36
39
Patients
Smoking and Alcoholic
Smoking Alcoholic
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Chart 7: Age distribution of the patients with SIRS 
 
 
 
Sex distribution of the sample 
 
Majority of the patients were males (90.6%, n=29). The following figure 
illustrates this. 
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Chart 8: Gender distribution of the patients with SIRS 
 
 
 
 
 
Clinical Presentation of the illness 
Majority of the patients reported epigastric guarding and tenderness (78.1%, 
n=25). The following picture depicts clinical presentation. 
 
Female
9%
Male
91%
Gender
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Chart 9: Clinical Presentation of the patients with SIRS 
 
 
 
Duration of illness 
The following image shows the duration of illness. Majority of them had two 
and three days of illness before seeking medical attention (34.4%, n=11). 
78.1
15.6
3.1 3.1
Epigastric guarding and
tenderness
Only epigastric tenderness Abdominal Distension No tenderness, Only upper
quadrant pain
Clinical Presentation
Clinical Presentation
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Chart 10: Duration of illness of the patients with SIRS 
 
 
 
 
Comorbid conditions  
The following picture shows the comorbid conditions of the patients. Diabetes 
and hypertension is the most common comorbid condition (12.5%, n=4).  
34.4
34.4
31.3
1
2
3
Duration of illness
Duration of illness
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Chart 11: Comorbidities of the patients with SIRS 
 
 
 
 
 
Smoking and alcoholism 
Out of 32 patients, 24 (75%) patients were smokers and 24 (75%) of them were 
alcoholics. 
 
69%
6%
12%
13%
Comorbidities
No Asthma Diabetic Hypertension
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Chart 12: Smoking and alcoholism of the patients with SIRS 
 
 
Patients with organ failure 
 
There were four patients with organ failure in the age group of 26 to 29 with 
duration of illness 1 to 3 days, all of them were smokers and alcoholics but with 
no comorbid conditions. All of them had pleural effusion on chest x-ray while 
24 24
Patients
Smoking and Alcoholic
Smoking Alcoholic
 
 
52 
 
USG abdomen and pelvis revealed peripancreatic fluid collection (n=2), bulky 
pancreas (n=1) and acute pancreatitis (n=1).  
TREATMENT GIVEN TO THE PATIENTS 
AT THE TIME OF ADMISSION 
Two 18 G venflon- fluids initiated at 150 ml/ hr 
Ryles tube insertion- for patients in SIRS 
NPO – for all patients 
Catheterise all patients 
Inj. Pantoprazole 40 mg iv stat 
Inj tramadol 100 mg im stat 
AT THE END OF 6 HOURS 
IVF- RL @ 250 ml/hr 
Nasal O2 for patients with  
                     - spo2 < 95% 
                     - organ failure 
Inj. Pantoprazole 40mg iv bd and Inj.Tramadol 2cc im bd given                   
URINE OUTPUT MONITORING 
Blood investigations repeated. 
Reassessments symptomatically and with blood investigations done at 12th hr, 
24th hr. and after 48 hours as shown in the master chart. 
Patients who failed to recover from SIRS and Organ failure were subjected to 
CECT Abdomen and ICU care was given. 
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Oral feeds started for patients who recovered at the end of 48 hours and patients 
with SIRS were started on NJ feeding. IV fluids reduced for those recovered 
from SIRS and the protocol based treatment continued. 
Only 6 patients with fever and necrotizing pancreatitis were given Inj.Imepenem 
1 g iv bd for 7 days. 
Clinical parameters and Imaging 
The following tables illustrate the clinical parameters at the time of admission, 
at 6th hour, 12th hour, 24th hour and 48th hour and their progression or recovery 
from disease. 
Parameters At admission 6th hour 12th hour 
No. Of patients 
requiring nasal 
o2 
32 30 20 
Patients with 
SIRS 
32 30 20 
Recovery from 
SIRS 
- 2 10 
Biliary 
pancreatitis 
4 4 4 
Organ failure 4 4 4 
Table 1: Clinical parameters and imaging at admission, 6th hour and 12th hour 
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Parameters At 24 hours 
No. Of patients requiring nasal o2 8 
Patients with SIRS 8 
Recovery from SIRS 24 
Require ICU care 11 
Biliary pancreatitis 4 
Organ failure 3 
Table 2: Clinical parameters and imaging at 24th hour 
 
 
Parameters At 24-48 hours 
No. Of patients requiring nasal o2 3 
Patients with SIRS 5 
Recovery from SIRS 27 
Biliary pancreatitis-resolved 4 
Organ failure 1 
Table 3: Clinical parameters and imaging at 24th– 48thhour 
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General Linear Model Repeated measures ANOVA 
Repeated measures ANOVA shows statistically significant variance for Pulse 
Rate, Respiratory Rate, Temperature and Total Count at the time of admission, 
at 6th hour, 12th hour, 24th hour and 48th hour. The following figures represent 
their variance and the tables show the values statistically. Significance was 
fixed at p<0.05.  
General Linear Model 
 
Tests of Within-Subjects Effects 
 Measure 
(Greenhouse-
Geisser values) 
Type III Sum 
of Squares 
df Mean 
Square 
F Sig. 
 Pulse rate 2095.650 3.276 639.753 38.607 .000 
RR 11.475 1.371 8.368 2.468 .001 
SPO2 1.537 1.414 1.088 2.242 .000 
Temperature 2.368 1.506 1.573 .553 .002 
TC 2703125.000 1.545 1749537.277 .363 .001 
S.Amylase 1211736.100 1.000 1211736.100 38.785 .000 
 
Table 4: Repeated measures ANOVA of variables of SIRS 
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The following figures illustrate the variance with time for the parameters of 
SIRS and other findings. 
Chart 13: Variance of pulse rate 
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Chart 14: Variance of Respiratory rate 
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Chart 15: Variance of sp02 
 
 
 
Chart 16: Variance of temperature 
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Chart 17: Variance of Total Count  
 
 
Chart 18: Variance of Serum Amylase 
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USG Abdomen and Pelvis 
 
 
USG Abdomen and Pelvis Frequency 
 Acute pancreatitis 13 
Bulky pancreas 6 
Bulky pancreas, GB Calculi + 1 
Peripancreatic fluid collection 15 
Peripancreatic fluid collection,GB Calculi + 1 
Table 5: USG abdomen and Pelvis 
 
X-ray abdomen erect and ECG 
 
These tests did not reveal any significant results. 
 
CT Abdomen and Pelvis at 24th hour 
Eight patients (25%, N=32) with SIRS  showed signs of acute necrotising 
pancreatitis while three patients with organ failure showed signs of acute 
necrotising pancreatitis.  
 
Comparison between USG abdomen/pelvis and CT abdomen/pelvis 
The following figure demonstrates the patients undergoing imaging. Only 
Eleven patients required both USG and CT.  
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Chart 19: CT/USG 
 
ICU transfer at 24th hour 
 
Eight patients (25%, N=32) with SIRS and three patients with organ failure 
were transferred to ICU. 
 
OGD Scopy 
 
The following table illustrates the findings from OGD scopy.  
 
OGD Scopy Frequency 
Normal 8 
 Duodenitis 13 
Pangastritis 15 
Table 6: OGD scopy 
 
 
 
 
8
3
32
4
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Organ Failure
CT/USG
USG CT
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Severity of pancreatitis  
Of the total patients presented, 25 patients had mild pancreatitis, 24 had 
moderately severe type and only 1 patient had Severe type of Acute Pancreatitis. 
 
 
 
Surgery 
Four patients out of 32 (9.4%) underwent laparoscopic cholecystectomy.  
 
 
 
Duration of stay at the hospital 
The following figure illustrates the duration of stay in the hospital for the 
patients with SIRS. The mean=8.72 days (S.D=4.595, N=32).  For patients with 
organ failure, it varied between 6 to 25 days.  
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Chart 20: Duration of stay in hospital 
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DISCUSSION 
A prospective study for ten months of all adult patients with clinical, laboratory 
Investigations and Imaging studies showing features of acute pancreatitis (first 
episode of acute pancreatitis as per the guidelines given by American College of 
Gastroenterologists) were subjected to aggressive fluid management irrespective 
of the scoring at the time of admission. Various factors associated with 
aetiology, clinical signs, sensitivity, treatment outcomes, complications, etc. 
were assessed and the Patients after institution of aggressive fluid management 
and analgesics were reassessed after 6 hours, 12hours, 24 hours and 48 hours to 
know the response to treatment based on symptomatic improvement and blood 
investigations. The age distribution of the participants was with mean age of 
33.14 (S.D=6.263) while a majority of the patients were males (92%, n=46). 
Majority of the patients reported epigastric guarding and tenderness (68%, 
n=34) and most of them had two days of illness before seeking medical 
attention (38%, n=19). Diabetes was the most common comorbid condition 
(12%, n=6) and 36 patients were smokers while 39 of them were alcoholics.  
The number of patients with SIRS was 32 in number a mean age distribution of 
33.72 (S.D=6.264, n=32). Majority of the patients were males (90.6%, n=29). 
Majority of the patients reported epigastric guarding and tenderness (78.1%, 
n=25) and most of them had two and three days of illness before seeking 
medical attention (34.4%, n=11). Diabetes and hypertension is the most 
 
 
65 
 
common comorbid condition (12.5%, n=4). 24 (75%) patients were smokers 
and 24 (75%) of them were alcoholics. There were four patients with organ 
failure in the age group of 26 to 29 with duration of illness 1 to 3 days, all of 
them were smokers and alcoholics but with no comorbid conditions. All of them 
had pleural effusion on chest x-ray while USG abdomen and pelvis revealed 
peripancreatic fluid collection (n=2), bulky pancreas (n=1) and acute 
pancreatitis (n=1).   
At 24th hour, there were three people with biliary pancreatitis that was resolved 
with 48 hours whereas the number of organ failure patients came down from 
three to one between 24th and 48th hour. Three patients out of 32 (9.4%) 
underwent laparoscopic cholecystectomy.  
 
Repeated measures ANOVA shows statistically significant variance for Pulse 
Rate, Respiratory Rate, Temperature and Total Count at the time of admission, 
at 6th hour, 12th hour, 24th hour and 48th hour. 
Eight patients (25%, N=32) with SIRS showed signs of acute necrotising 
pancreatitis while three patients with organ failure showed signs of acute 
necrotising pancreatitis. Eleven patients required both USG and CT. Eight 
patients (25%, N=32) with SIRS and three patients with organ failure were 
transferred to ICU at 24th hour.  
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All of them had moderately severe pancreatitis in SIRS while in organ failure 
two of them had moderately severe and one of them had severe and mild 
pancreatitis. The mean duration of stay in the hospital for the patients with SIRS 
was 8.72 days (S.D=4.595, N=32).  For patients with organ failure, it varied 
between 6 to 25 days.  There were 13 cases of duodenitis and 15 cases of 
pangastritis in OGD scopy.  
 
All these findings correlate with the guidelines outlined by the American 
College of Gastroenterology which has thrown light upon the management of 
cases of acute pancreatitis. As given in the protocol, clinical symptoms were 
used to establish the diagnosis of the disease with other tests of radiology like 
CT was reserved for patients with no improvement or with unclear diagnosis.  
Patients with SIRS and Organ failure were transferred to the ICU with 
aggressive hydration.  
At the end of 48 hours, of the 32 patients with SIRS and 4 patients with Organ 
Failure, 27 of patients with SIRS and 3 patients with organ failure recovered 
well. The remaining 5 patients with SIRS and 1 patient with organ failure 
recovered over the period of time slowly with hydration and analgesics. No 
deaths occurred in the study population proving that adherence to guidelines is 
must for optimum results. 
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STRENGTHS AND LIMITATIONS OF THE STUDY 
The major strengths of the study are the following: 
 This is a prospective study. 
 The sample size is good for a study period of 10 months. 
 The results were statistically analyzed and proven.   
The main limitations are as mentioned below: 
 The study can be extended for a longer period with a larger sample size 
for better results.  
 There are many studies based on the ACG Guidelines, but with changes 
made in it for managing the patients.No study has been conducted with 
the adherence of Guidelines. Even though this study has been done 
without deviating from the guidelines, further studies are required to test 
the universality, validity and reliability of the guidelines in different 
healthcare set up. 
 There are no literature reviews as such which has shown the adherence to 
the guidelines. 
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CONCLUSION 
 The present study emphasizes the management of acute pancreatitis 
according to the guidelines given by American College of 
Gastroenterology. Clinical symptoms and Blood investigations are used 
to establish the diagnosis of the disease along with radiological imaging 
like Ultrasonography. Other tests like CECT Abdomen and Pelvis are 
reserved for patients with no improvement or with unclear diagnosis after 
24 hours. Patients with SIRS and Organ failure should be transferred to 
the ICU with aggressive hydration if there are no signs of improvement 
after 24 hours of aggressive fluid management and analgesics.  
Laparoscopic cholecystectomy should be done in patients with biliary 
pancreatitis after complete recovery before discharge. 
 Antibiotics should given only in those patients who are having Infected 
pancreatic necrosis established clinically and confirmed by Contrast 
Enhanced CT. No patients in our study population presented with Acute 
Cholangitis and hence ERCP was not done in any. 
 With aggressive management, the clinical parameters denoting SIRS and 
organ failure improved.  
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 With the adherence of guidelines, there was no mortality of Acute 
pancreatitis and also the duration of stay in hospital decreased. But still, 
further studies are required to test the universality, validity in our setup. 
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LIST OF ABBREVIATIONS 
AP – Acute Pancreatitis 
NaHCO3 – Sodium Bicarbonate 
PaSC – Pancreatic Stellate Cell 
PSTI – Pancreatic Secretory Trypsin Inhibitor 
CECT – Contrast Enhanced Computed Tomography 
MRI – Magnetic Resonance Imaging 
IAP – Idiopathic Acute Pancreatitis 
BMI – Body Mass Index 
ABG – Arterial Blood Gas Analysis 
PR – Pulse Rate 
RR – Respiratory Rate 
ACG – American College of Gastroenterology 
BUN – Blood Urea Nitrogen 
HCT – Hematocrit 
WBC – White Blood Cells 
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ERCP – Endoscopic Retrograde Cholangio-Pancreatography 
MRCP – Magnetic Resonance Cholangio-Pancreatography 
NSAID – Non-Steroidal Anti Inflammatory Drug 
EUS – Endoscopic Ultrasound 
FNA – Fine Needle Aspiration 
Temp – Temperature 
FiO2 – Fraction of Inspired Oxygen 
SIRS – Systemic Inflammatory Response Syndrome 
SD – Standard Devation 
NPO – Nil Per Oral 
ANOVA – Analysis of Variance 
RL – Ringer Lactate 
NJ – Naso Jejunal 
ECG – Electrocardiography 
OGD – Oesophagoduodenoscopy 
USG – Ultrasonography 
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GOVT.STANLEY MEDICAL COLLEGE, CHENNAI- 600 001 
INFORMED CONSENT 
 
DISSERTATION TOPIC: “A STUDY ON OUTCOMES AND EFFICACY 
OF MANAGING ACUTE PANCREATITIS BASED ON GUIDELINES 
GIVEN BY AMERICAN COLLEGE OF GASTROENTROLOGISTS” 
 
PLACE OF STUDY: GOVT. STANLEY MEDICAL COLLEGE, CHENNAI 
 
NAME AND ADDRESS OF PATIENT: 
 
I, _____________________ have been informed about the details of the study 
in my own language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I understand that I can withdraw from the study at any point of time and even 
then, I will continue to receive the medical treatment as usual. 
I understand that I will not get any payment for taking part in this study. 
I will not object if the results of this study are getting published in any medical 
journal, provided my personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I 
would extend my full co-operation for this study. 
Name and Address of the Volunteer:  
 
 
Signature/Thumb impression of the Volunteer 
 
Date: 
 
Witnesses: 
(Signature, Name & Address) 
Date: 
 
 
 
Name and signature of investigator: 
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சுயஒப்புதல்படிவம் 
அரசுஸ்டான்லிமருத்துவகல்லூரி 
சென்னை – 1 
 
ஆராய்ச்சியின்சபயர் :   
ஆய்வு இடம் : அரசுஸ்டான்லிமருத்துவகல்லூரி 
 
___________________________________________________  என்கிற எைக்கு 
இந்த ஆராய்ச்சி பற்றிய முழு விவரங்களும் என் தாய்சமாழியில் தரப்பட்டை.  
இந்த ஆராய்ச்சி பற்றி முழுனமயாக புரிந்து சகாண்டடன். 
இதில் நான் பங்கு சபறுவதிைால் ஏற்படக்கூடிய அசெௌகரியங்கள் மற்றும் 
நன்னமகள் பற்றியும் சதரிந்து சகாண்டடன். 
இந்த ஆராய்ச்சியிலிருந்து என் சுய விருப்பபடி ,எந்த டநரமும் விலகி சகாள்ள 
முடியும் என்றும், அதைால் இம்மருத்துவமனையில் எைக்கு கினடக்க டவண்டிய 
மருத்துவ உதவிகள் அனைத்தும் எந்த பாரபட்ெமும் இல்லாமல் சதாடர்ந்து 
கினடக்கும் என்றும் சதரிந்து சகாண்டடன். 
இதில் பங்கு சபற எந்தவித ென்மாைமும் தர பட மாட்டாது என்று புரிந்து 
சகாண்டடன் . 
இந்த ஆராய்ச்சியின் முடிவுகள் , என்னை பற்றிய தனிப்பட்ட தகவல் ஏதும் 
தராமல் இருந்தால், மருத்துவம் ொர்ந்த பத்திரிக்னககளில் பிரசுரமாவதற்கு எதிர்ப்பு 
சதரிவிக்க மாட்டடன்.      
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இந்த ஆராய்ச்சியில் பங்கு சபற நான் என்ை செய்ய டவண்டும் என்று சதரிந்து 
சகாண்டடன் . அதன்படி முழு ஒத்துனைப்பு சகாடுக்க தயாராக உள்டளன். 
 
பங்கு சபறுபவரின் னகசயாப்பம்________________________________ 
டததி_______________ 
 
முகவரி_____________________________________________ 
 
ொட்சியாளரின்  னகசயாப்பம்___________________________________ 
டததி_______________ 
முகவரி_________________________________________________ 
 
ஆராய்ச்சியாளரின் னகசயாப்பம்_________________________________ 
டததி_____________ 
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“A STUDY ON THE OUTCOME AND EFFICACY OF MANAGING 
ACUTE PANCREATITIS BASED ON GUIDELINES GIVEN BY 
AMERICAN COLLEGE OF GASTROENTROLOGISTS 
 
Investigator: Dr.VAISHNAVI R.M., PG 2nd year – MS (General Surgery) 
Guide: Prof. Dr. LALITHKUMAR, Chief, Unit S6 
PATIENT INFORMATION MODULE 
You are being invited to be a subject in this study. 
Before you participate in this study, I am giving you the following details about 
this trial,  
All patients diagnosed with acute upper abdominal pain radiating to back with  
USG showing features of Acute Pancreatitis  will be included in this study. A 
detailed clinical history will be taken following a standardized proforma. A 
detailed clinical examination will be made and relevant basic investigations will 
be done at the time of admission. In case of being diagnosed as Acute 
Pancreatitis  you will be treated accordingly , following a standardised 
management protocol which will be evaluated by this study . The results arising 
from this study will be analyzed and used for academic purposes. You will be 
given clear instructions at every step and you are free to ask/ clarify any doubts. 
Your identity will remain confidential. You are free to withdraw from this trial 
at any point of time, without any prior notice &/ or without any medical or legal 
implications. 
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I request you to volunteer for this study. 
Thanking You, 
 
Investigator’s Sign        
 
Patient’s Sign 
                       (Name:                            ) 
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PROFORMA 
 
Investigator: Dr.VAISHNAVI R.M. , PG 3rd year – MS (General Surgery) 
 
Guide: Prof. Dr. LALITHKUMAR, Chief, Unit S6 
 
• NAME :      SL. NO: 
• AGE /SEX:  
• ADDRESS WITH CONTACT NUMBER:  
• IP NO:  
• DATE OF ADMISSION: 
• DATE OF SURGERY (IF ANY)  : 
DATE OF DISCHARGE / DEATH : 
• DURATION OF SYMPTOMS: 
 
HISTORY OF PRESENTING ILLNESS:  
 
PAST HISTORY:  
Whether a known case of DM/HTN/ Epilepsy / Bronchial Asthma 
H/O similar complaints in past. 
H/O chronic drug intake 
H/O any interventional procedure in past (i.eERCP ) ? 
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PERSONAL HISTORY : 
Alcoholic – How many years ? 
Smoker  
 
CLINICAL EXAMINATION 
 
GENERAL EXAMINATION:         TEMP:          P.R:       B.P:       R.R          
SPO2 
 
SYSTEMIC EXAMINATION: 
CVS : 
RS : 
PER ABDOMEN :    
 
 
 
 
CLINICAL DIAGNOSIS: 
 
 
BLOOD INVESTIGATIONS:  
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HB                                   PCV  
RBC                                    TC  
DC                                   PLT  
RBS                                   S. CALCIUM  
S.AMYLASE                      S. LIPASE 
B.UREA                         S.CREAT  
LFT 
T.B -                                    D.B – 
AST -                                  ALP – 
T.PROTEINS-                    S.ALBUMIN – 
PT -                                     APTT -                     INR –  
 
IMAGING:         
 
CHEST X-RAY:                                         ABDOMEN X-RAY: 
 
USG ABDOMEN  
 
TREATMENT GIVEN IN FIRST 6 HOURS : 
 
IV FLUIDS 
Inj. Pantoprazole 40 mg ivbd 
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Inj.Tramadol 2cc i.m.bd 
 
REASSESSMENT after 6 hours of Treatment : 
Whether any improvement in symptoms or not ? 
Clinical Examination – 
PR -                                BP -                             TEMP-                               RR- 
SPO2 -       
CVS-                                                  RS – 
P/A – 
URINE OUTPUT – 
BLOOD INVESTIGATIONS –  
HB 
TC 
PCV                                                   RFT- 
Treatment continued as per guidelines of fluid management based on urine 
output. 
At the end of 12 hours, 24 hours AND 48 Hours same parameters as above 
noted. 
CECT ABDOMEN AND PELVIS to be taken at the end of 24 hours if no 
improvement at the end of 24 hours with aggressive management. 
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PARAMETERS AT THE END OF 
12 HOURS 
AT THE END OF 
24 HOURS 
AT THE END OF 
48 HOURS 
SYMPTOMS 
 
 
   
PR    
BP    
TEMP    
RR    
SPO2    
URINE OUTPUT    
HB    
TC    
DC    
PCV    
S.AMYLASE    
S.LIPASE    
S.UREA    
S.CREATININE    
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TREATMENT AFTER REASSESSMENT 
IV FLUID management 
Antibiotics given or not ? 
Inj. Pantoprazole 40 mg ivbd 
Inj. Tramadol 2cc im bd 
 
IF PATIENT NEEDED ICU CARE ? 
IF ANTIBIOTICS GIVEN ? 
WHEN ORALS STARTED ? 
IF PATIENT REQUIRED ERCP ? 
IF PATIENT REQUIRED SURGERY ? 
CONDITION OF PATIENT AT DISCHARGE WITH FINAL DIAGNOSIS 
SEVERITY OF PANCREATITIS –  
 
MILD / MODERATELY SEVERE /    SEVERE 
 
DATE OF DISCHARGE/ DEATH – 
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MASTER CHART 
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KEY TO MASTER CHART 
 
PR – Pulse rate 
BP – Blood Pressure 
RR – Respiratory Rate 
SPO2 – Saturation 
M – Male 
 F – Female 
WNL  - Within Normal Limits 
CXR – Chest X- Ray PA view  
ECG – Electrocardiography 
RBS – Random Blood Sugar 
TGL – Triglyceride level 
T.B. – Total Bilirubin 
T.C. –  Total Counts 
PCV – Packed Cell Volume 
HB – Haemoglobin 
 
The values highlighted in Red shows the patients with SIRS. 
 
The yellow shaded boxes shows the patients with Organ Failure 
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